Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
3.90
Nov 06 • 3:59 PM ET Dollar change+0.13 Percentage change(3.45%)
Aftermarket Close
3.90
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
416.02M
Enterprise Value
198.29M
Income
-61.93M
Sales
0.00M
Book/sh
1.94
Cash/sh
2.04
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
17
IPO
Jun 20, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.01
P/C
1.91
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
29.52
Current Ratio
29.52
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.93
EPS next Y
-0.80
EPS next Q
-0.14
EPS this Y
57.07%
EPS next Y
-28.11%
EPS next 5Y
20.09%
EPS past 3/5Y
35.03% 17.54%
Sales past 3/5Y
- -
EPS Y/Y TTM
57.98%
Sales Y/Y TTM
-
EPS Q/Q
61.35%
Sales Q/Q
-
Insider Own
13.01%
Insider Trans
2.97%
Inst Own
84.67%
Inst Trans
16.64%
ROA
-51.57%
ROE
-55.66%
ROIC
-29.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
12.29%
SMA50
3.04%
SMA200
-27.24%
Trades
Shs Outstand
106.67M
Shs Float
92.79M
52W High
8.00 -51.25%
52W Low
2.42 61.16%
Volatility
12.09% 7.64%
ATR (14)
0.28
RSI (14)
56.35
Beta
0.57
Rel Volume
0.76
Avg Volume
1.39M
Volume
1,055,410
Perf Week
8.94%
Perf Month
23.03%
Perf Quarter
-14.10%
Perf Half Y
-46.72%
Perf YTD
-19.25%
Perf Year
49.43%
Perf 3Y
24.60%
Perf 5Y
-85.17%
Perf 10Y
-2.50%
Prev Close
3.77
Price
3.90
Change %
3.45%
Consensus
Strong Buy
Avg. Price Target
$10.75
Implied Upside
+175.6%
Analysts11incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 18, 2026Initiated
HH.C. Wainwright
Buy$12+207.7%
Mar 24, 2026Initiated
PPiper Sandler
Overweight$12+207.7%
Jan 23, 2026Resumed
LLeerink Partners
Outperform$8+105.1%
Dec 22, 2025Initiated
JEF logoJJefferies
Buy$69+1,669.2%
Nov 19, 2025Upgrade
MFG logoMMizuho
Neutral → Outperform$10+156.4%
Dec 05, 2024Downgrade
MFG logoMMizuho
Outperform → Neutral$23 → $1-74.4%
Sep 17, 2024Upgrade
JEF logoJJefferies
Hold → Buy$3.50 → $13+233.3%
Jun 05, 2024Downgrade
GS logoGGoldman
Neutral → Sell$3 → $2-48.7%
Oct 14, 2022Downgrade
TFC logoTTruist
Buy → Hold$90 → $10+156.4%
Oct 14, 2022Downgrade
GGuggenheim
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shenouda MagedChief Financial OfficerSep 09 '26Buy4.20120,200504,840920,200Sep 11 07:30 AM
Shenouda MagedChief Financial OfficerSep 10 '26Buy4.2579,800339,1501,000,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerSep 09 '26Buy4.18100,000418,0001,400,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerSep 10 '26Buy4.10100,000410,0001,500,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerDec 15 '25Buy4.1227,500113,3001,300,000Dec 16 09:30 AM
Shenouda MagedChief Financial OfficerDec 15 '25Buy4.1211,66548,060800,000Dec 16 09:30 AM
Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Pharm.D.Dr. Sergio Traversa M.B.A.
R.Ph.Mr. Maged S. Shenouda M.B.A.
COO & DirectorMr. Paul E. Kelly M.B.A.
M.B.A.Mr. Charles S. Ence CPA
VP & Head of Clinical OperationsMs. Gina DiGuglielmo